The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a huge mover today! About 395,502 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 40.32% since March 11, 2016 and is uptrending. It has outperformed by 34.86% the S&P500.
The move comes after 9 months negative chart setup for the $1.06B company. It was reported on Oct, 14 by Barchart.com. We have $19.34 PT which if reached, will make NASDAQ:SUPN worth $84.80 million less.
Analysts await Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings on November, 1. They expect $0.21 EPS, up 162.50% or $0.13 from last year’s $0.08 per share. SUPN’s profit will be $10.58M for 25.04 P/E if the $0.21 EPS becomes a reality. After $0.18 actual EPS reported by Supernus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 16.67% EPS growth.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. Northland Capital initiated Supernus Pharmaceuticals Inc (NASDAQ:SUPN) on Wednesday, October 28 with “Outperform” rating. As per Thursday, August 4, the company rating was maintained by Jefferies. The rating was downgraded by Northland Capital to “Market Perform” on Monday, July 18. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, July 18 report. Zacks downgraded the stock to “Hold” rating in Wednesday, August 26 report. As per Thursday, November 5, the company rating was maintained by Northland Capital.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.26 in 2016 Q2. Its up 0.11, from 1.15 in 2016Q1. The ratio is positive, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Millennium Mngmt Limited Liability Corp has 547,589 shares for 0.03% of their US portfolio. Envestnet Asset Mgmt accumulated 0% or 37,681 shares. The Arizona-based Arizona State Retirement Sys has invested 0.01% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Acadian Asset Limited Liability Com has 1.53M shares for 0.16% of their US portfolio. Castleark Mngmt Lc, a Illinois-based fund reported 444,161 shares. Scout Inc last reported 0.1% of its portfolio in the stock. Kistler last reported 0% of its portfolio in the stock. Panagora Asset Mngmt owns 330,677 shares or 0.03% of their US portfolio. The Pennsylvania-based Vanguard Grp Inc Inc has invested 0% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Nationwide Fund Advsr, a Pennsylvania-based fund reported 101,448 shares. The New York-based Mutual Of America Management Ltd Llc has invested 0.24% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). White Pine Lc holds 0.37% or 43,100 shares in its portfolio. Fincl Bank Of America Corporation De holds 0% or 375,010 shares in its portfolio. Ngam Advsrs Ltd Partnership reported 23,701 shares or 0.01% of all its holdings. Cubist Systematic Strategies Ltd Llc last reported 12,480 shares in the company.
Insider Transactions: Since September 16, 2016, the stock had 0 insider buys, and 1 insider sale for $50,000 net activity. Another trade for 2,000 shares valued at $50,000 was made by PATRICK GREGORY S on Friday, September 16.
More recent Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news were published by: Investorplace.com which released: “Supernus Pharmaceuticals Inc (SUPN) Stock Dips Despite Positive ADHD Data” on October 11, 2016. Also Seekingalpha.com published the news titled: “Supernus – SPN-812 Results And Thesis Update” on October 14, 2016. Seekingalpha.com‘s news article titled: “Supernus: Reasonable Valuation And Strong Future Growth” with publication date: October 05, 2016 was also an interesting one.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.